Stacy Kingsland, MD
Internal Medicine · Great Falls, MTNPI 1528160173
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$580
- Amgen$576
- Pfizer$387
- Merck$379
- GSK$350
- AbbVie$323
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$110%
- Food & beverage$4,87296%
- Education$1894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $580 |
| Amgen(2 entities) | 32 | $576 |
| Pfizer | 35 | $387 |
| Merck | 27 | $379 |
| GSK | 20 | $350 |
| AbbVie(2 entities) | 16 | $323 |
| Lilly USA, LLC | 19 | $312 |
| Astellas Pharma US Inc | 9 | $303 |
| Novo Nordisk | 18 | $299 |
| E.r. Squibb & Sons, L.L.C. | 11 | $210 |
| Exact Sciences | 7 | $170 |
| Novartis | 10 | $163 |
| Johnson & Johnson | 11 | $139 |
| Boehringer Ingelheim | 7 | $121 |
| Sanofi Pasteur Inc. | 6 | $114 |
| Corcept Therapeutics | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Mylan Specialty L.p. | 4 | $77 |
| Dexcom, Inc. | 3 | $55 |
| Bayer | 3 | $54 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Lundbeck LLC | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Sanofi | 1 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Acorda Therapeutics, Inc | 1 | $11 |
How this compares
$5,072 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $176,358 |
| OzempicSemaglutide | 102 | $129,289 |
| XareltoRivaroxaban | 127 | $106,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $49,189 |
| MounjaroTirzepatide | 34 | $44,548 |
| JanuviaSitagliptin Phosphate | 49 | $39,319 |
| TrulicityDulaglutide | 26 | $38,971 |
| JardianceEmpagliflozin | 35 | $35,348 |
| MyrbetriqMirabegron | 71 | $27,136 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $19,339 |
| LinzessLinaclotide | 24 | $17,463 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $12,203 |
| RybelsusSemaglutide | 12 | $11,432 |
| TradjentaLinagliptin | 12 | $9,009 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $387 | $176,358232 claims |
| Novo NordiskOzempic, Rybelsus | $299 | $140,721114 claims |
| Johnson & JohnsonXarelto | $139 | $106,954127 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $312 | $87,84472 claims |
| GSKTrelegy Ellipta | $350 | $49,18952 claims |
| Boehringer IngelheimJardiance, Tradjenta | $121 | $44,35747 claims |
| MerckJanuvia | $379 | $39,31949 claims |
| Astellas Pharma US IncMyrbetriq | $303 | $27,13671 claims |
| AbbVieLinzess | $323 | $17,46324 claims |
| NovartisEntresto | $163 | $7,55712 claims |
| AstraZenecaSymbicort | $580 | $3,85417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Great Falls
- Nicholas TrumGreat Falls$2K
- Bradford BergmanGreat Falls$2K
- Steven ChrzanowskiGreat Falls$2K
- Scott BurkGreat Falls$1K
- Kathleen BlairGreat Falls$1K
- Katherine ZitelloGreat Falls$682
- Eve GerasimouGreat Falls$661
- Berilonson OsiroGreat Falls$340
- James LeganGreat Falls$312
- Hanna BroniewskaGreat Falls$193
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.